GT Biopharma, Inc.GTBPNASDAQ
Loading
Asset Growth Recovery in ProgressRecovering
Percentile Rank82
5Y CAGR-29.9%
Year-over-Year Change
Year-over-year total asset growth rate
5Y CAGR
-29.9%/yr
Long-term compound
Percentile
P82
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 87.60% |
| Q3 2025 | -39.35% |
| Q2 2025 | 168.02% |
| Q1 2025 | -37.19% |
| Q4 2024 | -37.39% |
| Q3 2024 | -27.06% |
| Q2 2024 | -6.51% |
| Q1 2024 | -29.75% |
| Q4 2023 | -12.63% |
| Q3 2023 | -11.00% |
| Q2 2023 | -9.67% |
| Q1 2023 | 20.02% |
| Q4 2022 | -20.57% |
| Q3 2022 | -12.82% |
| Q2 2022 | -11.91% |
| Q1 2022 | -14.70% |
| Q4 2021 | -10.14% |
| Q3 2021 | -9.53% |
| Q2 2021 | 43.14% |
| Q1 2021 | 388.31% |
| Q4 2020 | 517.34% |
| Q3 2020 | -13.73% |
| Q2 2020 | 260.34% |
| Q1 2020 | -25.51% |
| Q4 2019 | -17.84% |
| Q3 2019 | -98.13% |
| Q2 2019 | 0.66% |
| Q1 2019 | 0.55% |
| Q4 2018 | -4.28% |
| Q3 2018 | -89.59% |
| Q2 2018 | -0.90% |
| Q1 2018 | 1.17% |
| Q4 2017 | -0.84% |
| Q3 2017 | 610661.90% |
| Q2 2017 | -82.35% |
| Q1 2017 | 852.00% |
| Q4 2016 | -84.38% |
| Q3 2016 | -55.80% |
| Q2 2016 | 878.38% |
| Q1 2016 | -31.48% |